JP2015526504A - Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ - Google Patents

Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ Download PDF

Info

Publication number
JP2015526504A
JP2015526504A JP2015529186A JP2015529186A JP2015526504A JP 2015526504 A JP2015526504 A JP 2015526504A JP 2015529186 A JP2015529186 A JP 2015529186A JP 2015529186 A JP2015529186 A JP 2015529186A JP 2015526504 A JP2015526504 A JP 2015526504A
Authority
JP
Japan
Prior art keywords
compound
formula
hcv
combination
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015529186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526504A5 (enExample
Inventor
ルアン，マリー−クロード
スヌーィズ，ジャン
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド, ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2015526504A publication Critical patent/JP2015526504A/ja
Publication of JP2015526504A5 publication Critical patent/JP2015526504A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015529186A 2012-08-31 2013-08-30 Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ Pending JP2015526504A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12182551.7 2012-08-31
EP12182551 2012-08-31
EP12185890.6 2012-09-25
EP12185890 2012-09-25
PCT/IB2013/058138 WO2014033668A2 (en) 2012-08-31 2013-08-30 Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir

Publications (2)

Publication Number Publication Date
JP2015526504A true JP2015526504A (ja) 2015-09-10
JP2015526504A5 JP2015526504A5 (enExample) 2016-09-23

Family

ID=49920362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529186A Pending JP2015526504A (ja) 2012-08-31 2013-08-30 Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ

Country Status (12)

Country Link
US (1) US20150209366A1 (enExample)
EP (1) EP2890378A2 (enExample)
JP (1) JP2015526504A (enExample)
KR (1) KR20150046083A (enExample)
CN (1) CN104780921A (enExample)
AU (1) AU2013311025A1 (enExample)
BR (1) BR112015003913A2 (enExample)
CA (1) CA2881052A1 (enExample)
IL (1) IL237049A0 (enExample)
MX (1) MX2015002684A (enExample)
RU (1) RU2015111491A (enExample)
WO (1) WO2014033668A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
CN106727516A (zh) * 2017-01-10 2017-05-31 山东省立医院 一种治疗丙型肝炎的药物组合物
US20210261111A1 (en) 2018-06-27 2021-08-26 Robert Bosch Gmbh Method for operating a hybrid powertrain with an electric machine, an internal combustion engine and a variable transmission

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502889A (ja) * 2005-07-29 2009-01-29 テイボテク・フアーマシユーチカルズ・リミテツド Ｃ型肝炎ウイルスの大員環式阻害剤
WO2011128378A1 (en) * 2010-04-13 2011-10-20 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
JP2012519158A (ja) * 2009-02-27 2012-08-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド Ｈｃｖの大環状阻害剤の無定形塩

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502889A (ja) * 2005-07-29 2009-01-29 テイボテク・フアーマシユーチカルズ・リミテツド Ｃ型肝炎ウイルスの大員環式阻害剤
JP2012519158A (ja) * 2009-02-27 2012-08-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド Ｈｃｖの大環状阻害剤の無定形塩
WO2011128378A1 (en) * 2010-04-13 2011-10-20 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside

Also Published As

Publication number Publication date
BR112015003913A2 (pt) 2017-07-04
US20150209366A1 (en) 2015-07-30
WO2014033668A3 (en) 2014-05-01
WO2014033668A2 (en) 2014-03-06
KR20150046083A (ko) 2015-04-29
CN104780921A (zh) 2015-07-15
RU2015111491A (ru) 2016-10-20
MX2015002684A (es) 2015-05-12
CA2881052A1 (en) 2014-03-06
IL237049A0 (en) 2015-03-31
EP2890378A2 (en) 2015-07-08
AU2013311025A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
JP2012502956A (ja) Ｈｃｖの大環状阻害剤とヌクレオシドの相乗性組み合わせ剤
WO2010031832A9 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
US20180250301A1 (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon
TW201532606A (zh) 使用化合物之組合治療ｃ型肝炎病毒感染
TW200815384A (en) Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
CN112351799A (zh) 具有硬化的hcv感染患者的治疗
JP2021515769A (ja) カプシド集合調節剤の投薬レジメン
JPWO2017155082A1 (ja) 抗肝腫瘍ウイルス剤
JP2015526504A (ja) Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ
JP2015519400A (ja) Ｈｃｖ感染症を治療するための治療剤の組合せ
US20140363396A1 (en) Once daily treatment of hepatitis c with ribavirin and taribavirin
JP5989635B2 (ja) Ｈｃｖの大環状阻害剤、非ヌクレオシドおよびヌクレオシドの組合せ
WO2008004653A1 (en) Prophylactic or therapeutic agent for viral disease
Tidwong et al. Pharmacological treatment for the Novel Coronavirus disease 2019 (COVID-19 Infection)
JP2017514834A (ja) Ｈｃｖ感染症を治療するための組合せ療法
HK1180222B (en) Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
HK1161833A (en) Synergistic combinations of a macrocyclic inhibitor of hcv and nucleoside
KR20140003203A (ko) 설폰아미드계 화합물을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171010